Our products are globally recognized for the prevention of organ rejection after kidney, heart and liver transplantation.
Astellas remains focused on transplantation, aiming at the development of new Immunosuppressive therapies. Through support for the conduct of nearly 100 European clinical trials, we strive to improve transplantation while developing new therapies and innovative therapies that target specific biological indicators.
At the same time, we support many Patient Organizations, giving them hope for the future.
Learn more about our therapeutic areas: